Company intelligence / Profile preview

Xintela AB

Ownership: Private
Employees: ~21
Development stage: Phase 1

Overview

Xintela has demonstrated safety and initial efficacy signals with its lead stem cell product XSTEM in Phase I/IIa trials for knee osteoarthritis. Other programs are at preclinical or early clinical stages. The company also develops antibody-based therapies targeting aggressive cancers such as triple-negative breast cancer and glioblastoma, currently at the preclinical stage.[1][3][5]

Therapeutic areas: PulmonologyDermatologyRheumatologyOncology
Modalities: Stem cell therapy (e.g., mesenchymal stem cells)Antibody-based therapies
Industry: Biotech

Drug pipeline

3 assets

XSTEM-VLU

2 more assets in the full pipeline.

Request access →

Partnerships

Agreement with Region Östergötland for GMP process development of cell therapy for burn patients[3]

Beyond the preview

Go deeper on Xintela AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xintela AB.

Explore the full profile